PTC Cuts Early-Stage Pipeline but Pushes Forward on FA Drug After Phase III Flop

Topline data from the registrational Phase III study MOVE-FA showed PTC Therapeutics’ Friedreich’s ataxia candidate vatiquinone did not meet its primary efficacy endpoint of significant improvement in disease progression, the company announced Tuesday. Despite these results, the company said it plans to talk with the FDA about a potential regulatory path forward for the treatment.